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Clinical Relevancy Statement {#jpen1030-sec-0050}
============================

This study compared placebo and 7 therapeutic regimens, and we recommend epinephrine ± corticosteroids and epinephrine ± hypertonic saline as the first choice for bronchiolitis treatment in children because of their outstanding performance with regard to clinical severity score and length of hospital stay.

Introduction {#jpen1030-sec-0060}
============

Infants and children are most susceptible to bronchiolitis.[1](#jpen1030-bib-0001){ref-type="ref"} Almost 3 million people are infected with this disease every year,[2](#jpen1030-bib-0002){ref-type="ref"} and most cases occur in spring and autumn. Low to moderate fever, coughing, running nose, wheezing, and sneezing are the usual symptoms. Respiratory syncytial virus (RSV) causes 50%--80% of bronchiolitis cases and is believed to be its primary cause.[3](#jpen1030-bib-0003){ref-type="ref"} In recent years, scientists found out that other viruses such as human rhinoviruses (HRV), coronaviruses, and bocavirus may also cause bronchiolitis.[4](#jpen1030-bib-0004){ref-type="ref"} Therefore, it is of great importance to determine the optimal therapeutic regimen.

Based on our investigation, most bronchiolitis regiments are controversial, and it is hard to draw a conclusive optimal treatment. Dexamethasone is considered efficacious because of significantly reduced hospitalization days and other clinical benefits.[5](#jpen1030-bib-0005){ref-type="ref"} However, there is also contradictory evidence.[6](#jpen1030-bib-0006){ref-type="ref"} One study proposed that 3% hypertonic saline (HS) ± epinephrine (EP) is more efficient than 0.9% normal saline ± EP in decreasing the length of hospitalization and other symptoms.[7](#jpen1030-bib-0007){ref-type="ref"} However, in another article, there was no significant discrepancy between the 2 treatments.[8](#jpen1030-bib-0008){ref-type="ref"} Through a 7‐day observation, 1 study said EP ± dexamethasone lacked efficacy.[9](#jpen1030-bib-0009){ref-type="ref"} However, another article said this combination was effective and even performed better than bronchodilator agents (BAs) in reducing bronchiolitis attacks.[10](#jpen1030-bib-0010){ref-type="ref"} In reference to BA, salbutamol is also considered an effective BA for infants with mild bronchiolitis. However, not all agreed with this suggestion.[11](#jpen1030-bib-0011){ref-type="ref"} Moreover, the combination of HS and BA was more effective than normal saline ± BA in decreasing symptoms,[12](#jpen1030-bib-0012){ref-type="ref"} but no difference was found in the clinical bronchiolitis severity score (CBSS).[13](#jpen1030-bib-0013){ref-type="ref"} Researchers have proved that EP is more efficient and safer than salbutamol.[14](#jpen1030-bib-0014){ref-type="ref"} Another study supported EP\'s efficacy but could not reach a conclusion on which agent was safer.[15](#jpen1030-bib-0015){ref-type="ref"} It seems that EP is more reliable than salbutamol. Some scientists found that HS is better at reducing admission days than 0.9% normal saline.[16](#jpen1030-bib-0016){ref-type="ref"} However, another article suggested that the application of EP, HS, salbutamol, and normal saline showed no significant discrepancy in their efficacy in treating infants with mild bronchiolitis.[17](#jpen1030-bib-0017){ref-type="ref"} In summary, there is no consensus in current research; therefore, more trials and analysis are required.

Several meta‐analyses (MAs) have been conducted to assess the efficacy and toxicity of different therapeutic regimens. These analyzed most mainstream treatments, including BA,[18](#jpen1030-bib-0018){ref-type="ref"}, [19](#jpen1030-bib-0019){ref-type="ref"}, [20](#jpen1030-bib-0020){ref-type="ref"} HS,[21](#jpen1030-bib-0021){ref-type="ref"} corticosteroids (CS),[22](#jpen1030-bib-0022){ref-type="ref"} EP,[23](#jpen1030-bib-0023){ref-type="ref"} antibiotics,[24](#jpen1030-bib-0024){ref-type="ref"} and montelukast.[25](#jpen1030-bib-0025){ref-type="ref"} However, MAs are pairwise comparisons and cannot display a network of multiple therapies. Therefore, due to a lack of direct evidence, we have not been able to evaluate the superiority and inferiority of other therapies. A new research method should be introduced to solve this problem. Network meta‐analysis (NMA) based on a Bayesian framework could compensate for the disadvantages of a traditional MA. NMA can make the best use of both direct and indirect evidence. In fact, this statistical approach has been applied for pharmaceutical selection and assessments more and more frequently.[24](#jpen1030-bib-0024){ref-type="ref"}

This NMA aimed to compare the efficacy of 7 therapeutic regimens---BA, HS, CS, EP, BA ± HS, EP ± CS, and EP ± HS---and the placebo (PBO). We used the clinical severity score (CSS) and length of hospital stay (LHS) as the assessment criteria. In summary, this article synthesizes and ranks 8 interventions in terms of efficacy and finally proposes the optimal drug selection for the treatment of bronchiolitis in children.

Methods and Materials {#jpen1030-sec-0070}
=====================

Literature Search {#jpen1030-sec-0080}
-----------------

The Embase, PubMed, and China National Knowledge Internet (CNKI) databases were searched for related publications. The cutoff date was August 26, 2016, and there were not any language restrictions. Our searching strategy included the use of keywords and correlated expressions such as *bronchiolitis*, *bronchodilator agents*, *hypertonic saline*, *epinephrine*, *corticosteroids*, *leukotriene inhibitors*, *antibacterial agents*, and *randomized controlled trial*. To avoid missing any relative studies, we checked the cited reference list of each selected articles. Two reviewers did this parallel literature screening independently.

Selection Criteria {#jpen1030-sec-0090}
------------------

There were 4 inclusion criteria: (1) patients were children who had a history of bronchiolitis or were diagnosed with bronchiolitis for at least 3 consecutive months, (2) study was a randomized controlled trial (RCT), (3) the study outcomes included CSS or LHS, and (4) there were enough relevant data concerning the outcomes.

Data Extraction {#jpen1030-sec-0100}
---------------

Two authors assessed the reports using the above selection criteria. If a study seemed to record a repeated patient sample, the report with the follow‐up period most similar to the other included studies was selected. A third author resolved any disagreements that arose. Extracted characteristics of each report are displayed in Table [1](#jpen1030-tbl-0001){ref-type="table"}. This includes but is not limited to the name of conductor(s), publication year, country, CSS and the standard they used, sample size, age, treatments, route, RSV positive, and duration of symptoms. Furthermore, we listed the Jadad scale of included studies. All records had a score of 4 or higher. This indicates that the studies retrieved were normative and reliable.

###### 

Baseline Characteristics of the Included Studies.[a](#jpen1030-tbl1-note-0002){ref-type="fn"}

                                                                                                                   Treatment A   Treatment B                                                                                         
  ---------------------------------------------------------------------------------- -------- ------------ ------ ------------- ------------- ----- ------------- --------- --------- ----- ---------- ----- ------------- --------- ---------
  Wu et al,[16](#jpen1030-bib-0016){ref-type="ref"} 2014, United States               Double       ED       RDAI       HS            inh       231  6.57 (5.17)    136/95     42/64    PBO     inh      216  6.40 (5.33)    118/98     42/71
  Ojha et al,[29](#jpen1030-bib-0029){ref-type="ref"} 2014, Nepal                     Double   Inpatient     NR        HS            inh       28   8.61 (5.74)     7/21       NR      PBO     inh      31   8.51 (4.24)     8/23       NR
  Jacobs et al,[8](#jpen1030-bib-0008){ref-type="ref"} 2014, United States            Double       ED       BSS      EP ± HS         inh       52   6.0 (3.9)       36/52     26/38    EP      inh      49   5.6 (3.3)       28/49     15/30
  Florin et al,[30](#jpen1030-bib-0030){ref-type="ref"} 2014, United States           Double   Outpatient   RDAI       HS            inh       31   7.2 (5.1)       15/16      NR      PBO     inh      31   6.1 (3.6)       13/18      NR
  Luo et al,[36](#jpen1030-bib-0036){ref-type="ref"} 2010, China                      Double   Inpatient    Wang     BA ± HS         inh       50   6.0 (4.3)       30/20     35/50    BA      inh      43   5.6 (4.5)       26/17     30/43
  Miraglia Del Giudice et al,[34](#jpen1030-bib-0034){ref-type="ref"} 2012, Italy     Double   Inpatient    RDAI     EP ± HS         inh       52   4.8 (2.3)       34/18     42/52    EP      inh      54   4.2 (1.6)       35/19     45/54
  Bertrand et al,[15](#jpen1030-bib-0015){ref-type="ref"} 2001, Chile                 Double   Inpatient    Tal        EP            inh       16   3.9 (1.6)        9/7      13/16    BA      inh      14   3.7 (2.25)       7/7      13/14
  Al‐Ansari et al,[37](#jpen1030-bib-0037){ref-type="ref"} 2010, Qatar                Double       ED       Wang     EP ± HS         inh       58   3.84 (2.84)     39/19     34/58    EP      inh      56   3.30 (2.43)     30/26     31/56
  Luo et al,[35](#jpen1030-bib-0035){ref-type="ref"} 2011, China                      Double   Inpatient    Wang       HS            inh       57   5.9 (4.1)       32/25     42/57    PBO     inh      55   5.8 (4.3)       31/24     40/55
  Tal et al,[43](#jpen1030-bib-0043){ref-type="ref"} 2006, Israel                     Double   Inpatient    Wang     EP ± HS         inh       21   2.8 (1.2)       10/11     18/21    EP      inh      20   2.3 (0.7)       13/7      15/20
  Anil et al,[17](#jpen1030-bib-0017){ref-type="ref"} 2010, Turkey                    Double   Outpatient   RDAI     EP ± HS         inh       39   9.4 (5.0)       29/10      NR      EP      inh      38   10.4 (5.7)      26/12      NR
                                                                                                                     BA ± HS         inh       36   9.7 (6.2)       23/13      NR      BA      inh      36   9.0 (6.2)       20/16      NR
                                                                                                                                                                                       PBO     inh      37   9.1 (4.4)       22/15      NR
  Beck et al,[42](#jpen1030-bib-0042){ref-type="ref"} 2007, Israel                    Double   Inpatient    Wang       EP            inh       12   4.9 (0.8)        8/4       NR      BA      inh      15   4.0 (1.35)      11/4       NR
  John et al,[14](#jpen1030-bib-0014){ref-type="ref"} 2006, India                     Double   Inpatient    RDAI       EP            inh       15   6.67 (3.01)     10/5       NR      BA      inh      15   6.73 (2.95)      9/6       NR
  Kabir et al,[39](#jpen1030-bib-0039){ref-type="ref"} 2009, Bangladesh               Double   Inpatient    RDAI       BA            inh       25   ---             15/10      NR      EP      inh      27   ---             17/10      NR
  Khashabi et al,[44](#jpen1030-bib-0044){ref-type="ref"} 2005, Iran                  Double   Outpatient   RDAI       EP            inh       24   8.9             5/19       NR      PBO     inh      24   7.9             9/15       NR
                                                                                                                       BA            inh       24   10.5            6/18       NR                                                    
  Kuyucu et al,[10](#jpen1030-bib-0010){ref-type="ref"} 2004, Turkey                  Double   Outpatient   RDAI     EP ± CS      inh ± im     23   7.2 (0.8)        NR        NR      EP    inh ± im   11   9.6 (1.3)        NR        NR
                                                                                                                     BA ± CS      inh ± im     23   7.9 (1.0)        NR        NR      BA    inh ± im   12   9.9 (1.7)        NR        NR
  Menon et al,[53](#jpen1030-bib-0053){ref-type="ref"} 1995, Canada                   Double   Outpatient   RDAI       BA            inh       21   ---              ---       NR      EP      inh      21   ---              ---       NR
  Plint et al,[9](#jpen1030-bib-0009){ref-type="ref"} 2009, Canada                    Double   Outpatient   RDAI     EP ± CS         inh       200  5              124/76    128/200   CS      inh      200  5              127/73    127/200
                                                                                                                       EP         inh ± po     199  5              122/77    129/199   PBO   inh ± po   201  5              120/81    136/201
  Can et al,[49](#jpen1030-bib-0049){ref-type="ref"} 1998, Turkey                     Double   Outpatient   RDAI       BA            inh       100  7.2 (4.2)       48/52      NR      PBO     inh      100  6.8 (2.1)       76/24      NR
  Chevallier et al,[54](#jpen1030-bib-0054){ref-type="ref"} 1995, France              Double   Inpatient     NR        BA            inh       16   ---             11/5      13/16    PBO     inh      17   ---             11/6      13/17
  Goh et al,[11](#jpen1030-bib-0011){ref-type="ref"} 1997, Singapore                  Double   Inpatient    Wang       BA            inh       30   5.7 (0.77)      24/6      15/30    PBO     inh      29   7.4 (0.89)      20/9      12/29
                                                                                                                       BA            inh       30   5.2 (0.67)      20/10     10/30                                                  
  Ipek et al,[13](#jpen1030-bib-0013){ref-type="ref"} 2011, Turkey                    Double   Outpatient   Wang       BA            inh       30   8.13 (4.75)     17/13      NR      HS      inh      30   8.4 (4.19)      17/13      NR
                                                                                                                     BA ± HS         inh       30   7.9 (3.57)      18/12      NR      PBO     inh      30   7.4 (3.08)      19/11      NR
  Scarlett et al,[33](#jpen1030-bib-0033){ref-type="ref"} 2012, United States         Double   Inpatient    RDAI       BA            inh       10   2.2 (1.07)       5/5       NR      PBO     inh      10   5.0 (3.96)       5/5       NR
  Tinsa et al,[38](#jpen1030-bib-0038){ref-type="ref"} 2009, Tunisia                  Double   Outpatient   RDAI       BA            inh       10   6.6 (2.02)      10/6       NR      PBO     inh      19   5.9 (2.3)       9/10       NR
  Totapally et al,[46](#jpen1030-bib-0046){ref-type="ref"} 2002, United States        Double   Inpatient     NR        BA            inh       10   5.1              7/3       NR      PBO     inh       9   5.8              2/9       NR
  Bentur et al,[45](#jpen1030-bib-0045){ref-type="ref"} 2005, Israel                  Double   Inpatient    Wang     EP ± CS         inh       29   3.3 (2.5)       14/15     29/29    EP      inh      32   3.8 (2.0)       14/18     32/32
  Berger et al,[50](#jpen1030-bib-0050){ref-type="ref"} 1998, Israel                  Double   Outpatient   Tal        CS            po        20   5.2 (0.7)        NR       10/20    PBO      po      18   4.8 (0.9)        NR       9/18
  Corneli et al,[41](#jpen1030-bib-0041){ref-type="ref"} 2007, United States          Double   Outpatient   RDAI       CS            po        304  5.1 (2.6)      190/114   85/127    PBO      po      294  5.1 (2.8)      178/116   81/142
  Klassen et al,[51](#jpen1030-bib-0051){ref-type="ref"} 1997, Canada                 Double   Inpatient    RDAI       CS            po        35   4.68            22/13     30/35    PBO      po      32   4.68            15/17     28/32
  Mesquita et al,[6](#jpen1030-bib-0006){ref-type="ref"} 2009, Paraguay               Double   Outpatient   RDAI       CS            po        33   7.3 (4)         19/14     17/29    PBO      po      32   5.9 (3)         15/17     19/23
  Richter and Seddon,[48](#jpen1030-bib-0048){ref-type="ref"} 1998, United Kingdom    Double   Inpatient     NR        CS            inh       21   4.08            12/9      16/21    PBO     inh      19   2.7             10/9      17/19
  Schuh et al,[5](#jpen1030-bib-0005){ref-type="ref"} 2002, Canada                    Double   Outpatient   RDAI       CS            po        36   6.1 (3.5)       20/16     15/28    PBO      po      34   6.9 (3.9)       23/11     15/30
  Sarrell et al,[47](#jpen1030-bib-0047){ref-type="ref"} 2002, Israel                 Double   Inpatient    Wang     BA ± HS         inh       33   12.7 (5.17)     18/15     27/33    BA      inh      32   12.3 (6.2)      18/14     25/32
  Grewal et al,[40](#jpen1030-bib-0040){ref-type="ref"} 2009, Canada                  Double   Outpatient   RDAI     EP ± HS         inh       23   5.6 (4.0)       14/9      19/23    EP      inh      23   4.4 (3.4)       14/9      18/22
  Reijonenet al,[52](#jpen1030-bib-0052){ref-type="ref"} 1995, Finland                Double   Inpatient    RDAI       EP            inh       24   10.6 (5.6)      14/10      NR      EP      inh      24   10.1 (5.7)      19/5       NR
                                                                                                                       BA            inh       27   9.9 (5.5)       16/11      NR      BA      inh      25   10.3 (7.5)      22/5       NR
  Bawazeer et al,[31](#jpen1030-bib-0031){ref-type="ref"} 2014, Saudi Arabia          Double       ED       RDAI     EP ± CS         inh       45   4.74 (2.84)     28/17     3/45     EP      inh      39   4.23 (2.46)     20/19     2/39
                                                                                                                     BA ± CS         inh       40   4.55 (2.21)     21/19     3/40     BA      inh      38   4.85 (2.35)     17/20     3/38
  Flores et al,[26](#jpen1030-bib-0026){ref-type="ref"} 2016, Portugal                Double       ED       Wang       HS            inh       33   3.3 (2.4)       18/15     29/33    PBO     inh      35   3.8 (2.5)       18/17     29/35
  Khanal et al,[28](#jpen1030-bib-0028){ref-type="ref"} 2015, Nepal                   Double   Outpatient   Wang     EP ± HS         inh       50   9.82 (5.06)     27/23      NR      EP      inh      50   9.51 (4.28)     21/29      NR
  Skjerven et al,[32](#jpen1030-bib-0032){ref-type="ref"} 2013, Norway                Double   Inpatient    RDAI       EP            inh       203  4.2 (2.9)      123/80      NR      PBO     inh      201  4.2 (2.8)      117/84      NR
  Zamani et al, [27](#jpen1030-bib-0027){ref-type="ref"} 2015, Iran                   Double   Inpatient    RDAI       BA            inh       35   14.1 (5.6)       NR        NR      HS      inh      35   12.6 (5.6)       NR        NR

BA, bronchodilator agent; BSS, bronchiolitis severity score; CS, corticosteroids; CSS, clinical severity score; ED, emergency department; EP, epinephrine; HS, hypertonic saline; im, intramuscular; inh, inhalation; NR, no report; PBO, placebo; po, per os; RDAI, Respiratory Distress Assessment Instrument; RSV, respiratory syncytial virus; ---, no data.

Clinical score standards are from: Wang EE, Milner RA, Navas L, Maj H. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections. *Am Rev Respir Dis*. 1992;145:106‐109. Tal A, Bavilski C, Yohai D, Bearman JE, Gorodischer R, Moses SW. Dexamethasone and salbutamol in the treatment of acute wheezing in infants. *Pediatrics*. 1983;71:13‐18.
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Statistical Analysis {#jpen1030-sec-0110}
--------------------

This study built a random‐effects network based on a Bayesian framework using the Markov chain Monte Carlo methods. We plotted networks of the curative outcomes of several studies and specified the relation by mean difference (MD), standardized MD (SMD), and 95% credible interval (CI) across experiments to compare different bronchiolitis treatments. The surface under the cumulative ranking curve (SUCRA) was used to calculate the probability of the curative effect. It separately ranked each therapy on CSS and LHS. Scores ranged from 0 to 1, and a higher score indicated a greater efficacy. Statistical heterogeneity across the studies was assessed using heat plots and node‐splitting plots. All computations were performed using the STATA 13.1 (StataCorp LP, College Station, TX) and R 3.3.1 (Lucent Technologies, Jasmine Hill, NJ) software.

Results {#jpen1030-sec-0120}
=======

Process of Eligible Study Selection {#jpen1030-sec-0130}
-----------------------------------

We screened out 2312 records using the search strategies previously described. A total of 1914 records remained after duplicates were removed, and 1874 articles were discarded due to unrelated treatment, comparison, or lack of quantitative outcomes. Forty articles were believed to have a high quality and valuable data.[5](#jpen1030-bib-0005){ref-type="ref"}, [6](#jpen1030-bib-0006){ref-type="ref"}, [8](#jpen1030-bib-0008){ref-type="ref"}, [9](#jpen1030-bib-0009){ref-type="ref"}, [10](#jpen1030-bib-0010){ref-type="ref"}, [11](#jpen1030-bib-0011){ref-type="ref"}, [13](#jpen1030-bib-0013){ref-type="ref"}, [14](#jpen1030-bib-0014){ref-type="ref"}, [15](#jpen1030-bib-0015){ref-type="ref"}, [16](#jpen1030-bib-0016){ref-type="ref"}, [17](#jpen1030-bib-0017){ref-type="ref"}, [26](#jpen1030-bib-0026){ref-type="ref"}, [27](#jpen1030-bib-0027){ref-type="ref"}, [28](#jpen1030-bib-0028){ref-type="ref"}, [29](#jpen1030-bib-0029){ref-type="ref"}, [30](#jpen1030-bib-0030){ref-type="ref"}, [31](#jpen1030-bib-0031){ref-type="ref"}, [32](#jpen1030-bib-0032){ref-type="ref"}, [33](#jpen1030-bib-0033){ref-type="ref"}, [34](#jpen1030-bib-0034){ref-type="ref"}, [35](#jpen1030-bib-0035){ref-type="ref"}, [36](#jpen1030-bib-0036){ref-type="ref"}, [37](#jpen1030-bib-0037){ref-type="ref"}, [38](#jpen1030-bib-0038){ref-type="ref"}, [39](#jpen1030-bib-0039){ref-type="ref"}, [40](#jpen1030-bib-0040){ref-type="ref"}, [41](#jpen1030-bib-0041){ref-type="ref"}, [42](#jpen1030-bib-0042){ref-type="ref"}, [43](#jpen1030-bib-0043){ref-type="ref"}, [44](#jpen1030-bib-0044){ref-type="ref"}, [45](#jpen1030-bib-0045){ref-type="ref"}, [46](#jpen1030-bib-0046){ref-type="ref"}, [47](#jpen1030-bib-0047){ref-type="ref"}, [48](#jpen1030-bib-0048){ref-type="ref"}, [49](#jpen1030-bib-0049){ref-type="ref"}, [50](#jpen1030-bib-0050){ref-type="ref"}, [51](#jpen1030-bib-0051){ref-type="ref"}, [52](#jpen1030-bib-0052){ref-type="ref"}, [53](#jpen1030-bib-0053){ref-type="ref"}, [54](#jpen1030-bib-0054){ref-type="ref"} Figure [1](#jpen1030-fig-0001){ref-type="fig"} shows the entire literature screening process. Table [1](#jpen1030-tbl-0001){ref-type="table"} displays all included studies. The results of the Jadad scale on included studies are shown in Supplementary Table S1. Eight therapies, including the PBO, are synthesized into 1 network in Figure [2](#jpen1030-fig-0002){ref-type="fig"}.

![Flowchart.](JPEN-42-186-g001){#jpen1030-fig-0001}

![Network diagram of all included studies. Each node represents a treatment type; the number in circles represents the number of people involved in all included studies and the widths of lines with numbers between 2 nodes represent the number of study involved in the head‐to‐head comparison. BA, bronchodilator agent; CS, corticosteroids; EP, epinephrine; HS, hypertonic saline; PBO, placebo.](JPEN-42-186-g002){#jpen1030-fig-0002}

NMA on the Efficacy of 7 Therapeutic Regimens and PBO {#jpen1030-sec-0140}
-----------------------------------------------------

This NMA synthesized and made comparison among the PBO and 7 therapeutic regimens, including BA, HS, BA ± HS, CS, EP, EP ± CS, and EP ± HS (Table [2](#jpen1030-tbl-0002){ref-type="table"}). We found that all 7 therapeutic regimens showed no statistical difference from PBO with regard to CSS. Among the 7 therapies, BA performed better than CS (SMD, --0.36; 95% CI, --0.64 to --0.09), the other 5 displayed no significant statistical difference. With regard to LHS, EP and EP ± HS had an advantage over PBO (EP: MD, --2.23; 95% CI, --4.04 to --0.52; EP ± HS: MD, --2.70; 95% CI, --4.81 to --0.75). Moreover, EP and EP ± HS were also more efficient than BA (EP: MD, --1.89; 95% CI, --3.65 to --0.17; EP ± HS: MD, --2.37; 95% CI, --4.42 to --0.38). When it comes to LHS, these 2 therapies had a better efficacy than the others. The same conclusion can also be drawn from the forest plots (Figure [3](#jpen1030-fig-0003){ref-type="fig"}).

###### 

Comparisons of Bronchiolitis Treatments With Regard to Clinical Outcomes.[a](#jpen1030-tbl2-note-0002){ref-type="fn"}

  Clinical Severity Score (CSS)                                                                                                                                                                            
  ------------------------------- ------------------------- -------------------------------------- ------------------------- ------------------------- ------------------------- ------------------------- --------------------------
  **BA**                           --0.07 (--0.34 to 0.20)   --**0.36 (**--**0.64 to**--**0.09)**   --0.13 (--0.33 to 0.06)   --0.13 (--0.37 to 0.11)   --0.02 (--0.39 to 0.34)   --0.18 (--0.40 to 0.04)   --0.21 (--0.41 to--0.02)
  0.07 (--0.20 to 0.34)                **BA** ± **HS**             --0.29 (--0.62 to 0.04)          --0.06 (--0.39 to 0.27)   --0.06 (--0.42 to 0.30)    0.05 (--0.40 to 0.50)    --0.11 (--0.36 to 0.13)   --0.14 (--0.41 to 0.13)
  **0.36 (0.09--0.64)**             0.29 (--0.04 to 0.62)                   **CS**                   0.23 (--0.11 to 0.56)     0.23 (--0.13 to 0.60)     0.34 (--0.12 to 0.79)     0.18 (--0.08 to 0.44)     0.15 (--0.05 to 0.35)
  0.13 (--0.06 to 0.33)             0.06 (--0.27 to 0.39)          --0.23 (--0.56 to 0.11)                  **EP**             0.01 (--0.18 to 0.19)     0.11 (--0.20 to 0.41)    --0.05 (--0.34 to 0.24)   --0.08 (--0.35 to 0.19)
  0.13 (--0.11 to 0.37)             0.06 (--0.30 to 0.42)          --0.23 (--0.60 to 0.13)          --0.01 (--0.19 to 0.18)       **EP** ± **CS**        0.11 (--0.25 to 0.46)    --0.05 (--0.38 to 0.27)   --0.08 (--0.39 to 0.23)
  0.02 (--0.34 to 0.39)            --0.05 (--0.50 to 0.40)         --0.34 (--0.79 to 0.12)          --0.11 (--0.41 to 0.20)   --0.11 (--0.46 to 0.25)       **EP** ± **HS**       --0.16 (--0.58 to 0.27)   --0.19 (--0.60 to 0.22)
  0.18 (--0.04 to 0.40)             0.11 (--0.13 to 0.36)          --0.18 (--0.44 to 0.08)           0.05 (--0.24 to 0.34)     0.05 (--0.27 to 0.38)     0.16 (--0.27 to 0.58)            **HS**            --0.03 (--0.20 to 0.14)
  0.21 (--0.02 to 0.41)             0.14 (--0.13 to 0.41)          --0.15 (--0.35 to 0.05)           0.08 (--0.19 to 0.35)     0.08 (--0.23 to 0.39)     0.19 (--0.22 to 0.60)     0.03 (--0.14 to 0.20)            **PBO**

  Length of Hospital Stay (LHS)                                                                                                                                                                    
  -------------------------------------- ------------------------- ------------------------- ------------------------- ------------------------- ----------------------- ------------------------- --------------------------------------
  **BA**                                  --0.10 (--2.15 to 1.95)    0.66 (--2.31 to 3.55)     **1.89 (0.17--3.65)**     2.20 (--0.58 to 4.98)    **2.37 (0.38--4.42)**    0.44 (--1.32 to 2.08)          --0.34 (--2.19 to 1.43)
  0.10 (--1.95 to 2.15)                       **BA** ± **HS**        0.75 (--2.88 to 4.30)     1.99 (--0.72 to 4.69)     2.30 (--1.19 to 5.75)    2.46 (--0.42 to 5.38)    0.53 (--2.24 to 3.12)          --0.24 (--3.04 to 2.45)
  --0.66 (--3.55 to 2.31)                 --0.75 (--4.30 to 2.88)           **CS**             1.24 (--1.59 to 4.17)     1.54 (--2.01 to 5.22)    1.71 (--1.30 to 4.85)   --0.22 (--2.73 to 2.29)         --0.99 (--3.30 to 1.34)
  --**1.89 (**--**3.65 to**--**0.17)**    --1.99 (--4.69 to 0.72)   --1.24 (--4.17 to 1.59)           **EP**             0.30 (--1.87 to 2.48)    0.47 (--0.55 to 1.52)   --1.46 (--3.36 to 0.32)   --**2.23 (**--**4.04 to**--**0.52)**
  --2.20 (--4.98 to 0.58)                 --2.30 (--5.75 to 1.19)   --1.54 (--5.22 to 2.01)   --0.30 (--2.48 to 1.87)       **EP** ± **CS**       0.17 (--2.21 to 2.59)   --1.76 (--4.67 to 1.00)         --2.53 (--5.35 to 0.21)
  --**2.37 (**--**4.42 to**--**0.38)**    --2.46 (--5.38 to 0.42)   --1.71 (--4.85 to 1.30)   --0.47 (--1.52 to 0.55)   --0.17 (--2.59 to 2.21)      **EP** ± **HS**      --1.93 (--4.12 to 0.09)   --**2.70 (**--**4.81 to**--**0.75)**
  --0.44 (--2.08 to 1.32)                 --0.53 (--3.12 to 2.24)    0.22 (--2.29 to 2.73)     1.46 (--0.32 to 3.36)     1.76 (--1.00 to 4.67)    1.93 (--0.09 to 4.12)           **HS**                  --0.77 (--1.75 to 0.25)
  0.34 (--1.43 to 2.19)                    0.24 (--2.45 to 3.04)     0.99 (--1.34 to 3.30)     **2.23 (0.52--4.04)**     2.53 (--0.21 to 5.35)    **2.70 (0.75--4.81)**    0.77 (--0.25 to 1.75)                  **PBO**

BA-- bronchodilator agent; CS, corticosteroids; EP, epinephrine; HS, hypertonic saline; PBO, placebo.

Standardized mean difference and 95% credible interval (CI) for CSS. Mean difference and 95% CI for LHS. Bold values represent significant results.
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![Forest plots for clinical severity score change and length of hospital stay of different treatment effects. BA, bronchodilator agent; CI, credible interval; CS, corticosteroids; EP, epinephrine; HS, hypertonic saline; MD, mean difference; MS, mean difference; PBO, placebo; SMD, standardized mean difference.](JPEN-42-186-g003){#jpen1030-fig-0003}

Consistency Assessments {#jpen1030-sec-0150}
-----------------------

This NMA used both direct and indirect information; therefore, it was of great importance to assess the consistency of evidence collected. Node splitting (Table [3](#jpen1030-tbl-0003){ref-type="table"}) and heat plots (Supplementary Figure S1) were applied to check the consistency between direct and indirect evidence. According to Table [3](#jpen1030-tbl-0003){ref-type="table"}, there is a discrepancy between BA and HS (*P* = .025, less than the significance level of .05). The heat plots (Supplementary Figure S1) show no obvious inconsistency.

###### 

Node‐Splitting Results of Clinical Severity Score (CSS) and Heterogeneity Analysis.[a](#jpen1030-tbl3-note-0002){ref-type="fn"}

                   Direct   Indirect   Difference                            
  ---------------- -------- ---------- ------------ ------- -------- ------- ----------
  BA vs PBO        --0.41   0.32       --0.36       0.54    --0.05   0.63    .940
  BA ± HS vs PBO   --0.54   0.83       --1.32       0.61    0.78     1.03    .451
  EP vs PBO        --1.29   0.47       --0.82       0.47    --0.47   0.66    .482
  HS vs PBO        0.07     0.34       --0.21       0.81    0.27     0.88    .755
  BA ± HS vs BA    --0.84   0.47       0.79         1.31    --1.63   1.40    .243
  EP vs BA         --0.42   0.27       --2.00       0.65    1.58     0.70    **.025**
  EP ± CS vs BA    --2.36   0.64       --0.89       0.61    --1.47   0.88    .095
  HS vs BA         0.27     0.59       0.52         0.47    --0.25   0.76    .743
  HS vs BA ± HS    --0.05   0.79       1.86         0.66    --1.91   1.03    .062
  EP ± CS vs EP    --0.85   0.43       --2.02       1.25    1.17     1.31    .370
  EP ± HS vs EP    --0.34   0.33       3.20         25.93   --3.54   25.93   .891

BA, bronchodilator agent; CS, corticosteroids; EP, epinephrine; HS, hypertonic saline; PBO, placebo.

Standardized mean difference (SMD) and standard deviation (SD) for CSS. Bold values represent significant results.

John Wiley & Sons, Ltd.
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Ranking 8 Therapies With SUCRA {#jpen1030-sec-0160}
------------------------------

In this study, 2 SUCRA plots (Figure [4](#jpen1030-fig-0004){ref-type="fig"}) on the related outcomes were constructed. In relation to CSS, EP ± CS ranked first and EP ± HS ranked second. EP or BA ± HS also demonstrated a strong performance. Of the 7 therapies, HS performed the worst. With regard to LHS, all treatments were more efficient than PBO. Among them, EP ± HS was suggested to be the best therapeutic regimen. EP ± CS and EP ± HS showed a great curative effect both in CSS and LHS. EP ranked third after the 2 outcomes, and while BA ± HS was the strongest performer in terms of CSS, it scored poorly in LHS.

![Ranking grams for clinical severity score change and length of hospital stay of different treatment effects. The surface under the cumulative ranking curve (SUCRA) values are listed in the legend. BA, bronchodilator agent; CS, corticosteroids; EP, epinephrine; HS, hypertonic saline; PBO, placebo.](JPEN-42-186-g004){#jpen1030-fig-0004}

In all, EP ± CS and EP ± HS proved to be the optimal treatments for bronchiolitis. EP also had a good curative effect.

Publication Bias {#jpen1030-sec-0170}
----------------

According to the symmetrical characteristics of the funnel plots, no obvious publication bias is observed (Supplementary Figure S2).

Discussion {#jpen1030-sec-0180}
==========

According to SUCRA, EP ± CS ranks first in CSS and second in LHS, while EP ± CS take first place in LHS and second in CSS. This result exhibits that EP ± CS and EP ± HS have an outstanding performance with respect to efficacy. EP is a hormone and neurotransmitter, and it is also used as medication.[55](#jpen1030-bib-0055){ref-type="ref"} It originates from some neurons and paranephros.[55](#jpen1030-bib-0055){ref-type="ref"} EP can control blood glucose, pupil dilation, cardiac output, and blood flow by affecting α and β receptors. CS is a type of steroid hormone that is extracted from vertebrates' adrenal cortex or some synthetic analogues of hormones. CS is usually applied to physiologic processes such as protein catabolism, immune response, and so on.[56](#jpen1030-bib-0056){ref-type="ref"} It is a widely used intervention, and there are several kinds of HS concentrations, the most common being 3%. Three percent HS plays an important role in treating severe hyponatremia, acutely increased intracranial pressure, and critical care settings.[57](#jpen1030-bib-0057){ref-type="ref"} Inhalational HS is believed to have a curative effect on respiratory problems such as bronchiolitis.[58](#jpen1030-bib-0058){ref-type="ref"} Based on our research, a combination of these medicines showed a better efficacy than therapy with the use of 1 treatment alone.

EP ± HS exhibited an outstanding curable effect in previous individual research and MAs. This research reveals that EP ± HS can successfully reduce LHS and CSS. This conclusion was confirmed by Miraglia Del Giudice et al,[7](#jpen1030-bib-0007){ref-type="ref"} who also demonstrated that 3% HS ± EP was able to decrease symptoms and LHS. A report that claimed that 3% HS ± EP could improve CSS in infants with mild to moderate viral bronchiolitis[28](#jpen1030-bib-0028){ref-type="ref"} also supports our conclusions. Some research also took into consideration the concentration of HS as this may have a significant effect on efficacy. For example, it was demonstrated that 5% HS ± EP and 3% HS ± EP had a better performance in improving CSS than 0.9% normal saline. However, 5% HS ± EP had a stronger potential to reduce clinical severity than 3% HS ± EP.[37](#jpen1030-bib-0037){ref-type="ref"} This reminded us of the importance of concentration and why we should pay more attention to it in clinical practice. EP ± CS also had a brilliant performance with respect to CSS and LHS. Through the investigation and study of infants with bronchiolitis treated in the emergency department, it was found that dexamethasone (a kind of CS) with EP may effectively reduce LHS.[9](#jpen1030-bib-0009){ref-type="ref"} In addition, another study of infants with acute bronchiolitis implied that EP ± CS (dexamethasone) was significantly different from BA.[10](#jpen1030-bib-0010){ref-type="ref"} This is consistent with our conclusions.

However, some researches and MAs had contradicting evidence to our results. A study that focused on the inhalation of 7% HS ± EP for patients with moderate to severe acute bronchiolitis[8](#jpen1030-bib-0008){ref-type="ref"} implied that 7% HS ± EP did not appear to show any significant clinical decrease in CSS compared with 0.9% normal saline ± EP. Grewal et al[40](#jpen1030-bib-0040){ref-type="ref"} conducted a randomized trial of severe bronchiolitis in the emergency department and concluded that 3% HS ± EP does not significantly reduce CSS compared with normal saline. Similarly, another experiment also could not find any difference in infants with mild bronchiolitis.[17](#jpen1030-bib-0017){ref-type="ref"} The above studies did not accord with most published results, but we could not simply omit them. Furthermore, some controversy also exists in the effect of EP ± CS. An RCT showed that EP ± CS did not play a role in bronchiolitis management for first‐time wheezing infants due to a lack of positive effect on CSS and LHS.[31](#jpen1030-bib-0031){ref-type="ref"} This result was not reflected in our SUCRA results, and the inconsistency may be caused by several reasons. First, this NMA synthesized experimental data of HS without the consideration of HS concentration. The curative effect may be sensitive to concentration. Second, there may be some inconsistency between direct and indirect evidence. Last but not least, this study built a random‐effects network based on a Bayesian framework using the Markov chain Monte Carlo methods, but it did not have an unbiased estimator.[59](#jpen1030-bib-0059){ref-type="ref"} This may consequently affect the SUCRA values.

In summary, this NMA synthesized 7 therapeutic regimens as well as the PBO and ranked them on curative effect on CSS and LHS. This NMA adopted \>1 outcome to thoroughly assess the treatments and to make sure we had better understanding of these 7 interventions. Furthermore, this study takes into consideration a greater volume of data. This is the main advantage of an NMA over a traditional MA and individual trials. All research involved in this study included high‐quality RCTs.

Some limitations affect our NMA results. First, there is a large discrepancy in sample size among the 7 treatments. This may have a significant impact on the corresponding 95% CI. The group partition was also very broad and did not consider intervention dose, patient age, patient health status, and so on. These factors should be further addressed. To some extent, a subgroup NMA could make up for these issues. This study could also have possibly missed some key data due to the omission of unpublished research. This study did not take into consideration any adverse effects, and as safety is an important aspect in assessing treatment, future studies should consider toxicity files.

Conclusion {#jpen1030-sec-0190}
==========

EP ± CS and EP ± HS had outstanding efficacy performance in terms of CSS and LHS and should be the first choice of bronchiolitis treatment in children. However, this NMA did not analyze the adverse effects of these 2 combined therapies; therefore, further research is still required.
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